ARTICLE | Clinical News
Alnylam preclinical data
September 21, 2015 7:00 AM UTC
In a rat model of PH1, once-weekly subcutaneous ALN-GO1 reduced mean urinary oxalate levels by up to 98%. Additionally, ALN-GO1 produced up to 99% silencing of glycolate oxidase mRNA in non-human pri...